These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38810205)

  • 1. Tumor-Only Sequencing: A Story Only Half Told.
    Ceyhan-Birsoy O; Stadler ZK
    JCO Precis Oncol; 2024 May; 8():e2400226. PubMed ID: 38810205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-only sequencing for oncology management: Germline-focused analysis and implications.
    George A; Turnbull C
    Genes Chromosomes Cancer; 2021 May; 60(5):352-357. PubMed ID: 33222309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward Concurrent Testing for Somatic and Germline Variants in Cancer Patients.
    Mandelker D
    Clin Cancer Res; 2016 Aug; 22(16):3987-8. PubMed ID: 27307597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Based Genetic Testing and Familial Cancer Risk.
    Forman A; Sotelo J
    Cold Spring Harb Perspect Med; 2020 Aug; 10(8):. PubMed ID: 31570381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives.
    Bennett S; Alexander E; Fraser H; Bowers N; Wallace A; Woodward ER; Lalloo F; Quinn AM; Huang S; Schlecht H; Evans DG
    Eur J Hum Genet; 2021 May; 29(5):861-871. PubMed ID: 33654310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitfalls in variant annotation for hereditary cancer diagnostics: The example of Illumina® VariantStudio®.
    Kalfakakou D; Konstantopoulou I; Yannoukakos D; Fostira F
    Genomics; 2021 Jan; 113(1 Pt 2):748-754. PubMed ID: 33053411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Germline Variants in Tumor Genomic Sequencing Analysis.
    Montgomery ND; Selitsky SR; Patel NM; Hayes DN; Parker JS; Weck KE
    J Mol Diagn; 2018 Jan; 20(1):123-125. PubMed ID: 29249243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid identification of germline mutations in retinoblastoma by protein truncation testing.
    Tsai T; Fulton L; Smith BJ; Mueller RL; Gonzalez GA; Uusitalo MS; O'Brien JM
    Arch Ophthalmol; 2004 Feb; 122(2):239-48. PubMed ID: 14769601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
    Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
    Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Somatic" Tumor Genomic Profiling and Potential Germline Implications: Ethical Considerations for Children with Cancer.
    Knapp E
    J Law Med Ethics; 2020 Dec; 48(4):778-783. PubMed ID: 33404327
    [No Abstract]   [Full Text] [Related]  

  • 14. Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model.
    Johnson LM; Sykes AD; Lu Z; Valdez JM; Gattuso J; Gerhardt E; Hamilton KV; Harrison LW; Hines-Dowell SJ; Jurbergs N; McGee RB; Nuccio R; Ouma AA; Pritchard M; Quinn EA; Baker JN; Mandrell BN; Nichols KE
    Cancer; 2019 Jul; 125(14):2455-2464. PubMed ID: 30901077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.
    Petersen AH; Aagaard MM; Nielsen HR; Steffensen KD; Waldstrøm M; Bojesen A
    Eur J Hum Genet; 2016 Aug; 24(8):1104-11. PubMed ID: 26733283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole Exome Sequencing: The Next Phase of Genetics Care.
    Mahon SM
    Oncol Nurs Forum; 2016 Mar; 43(2):249-52. PubMed ID: 26906136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    Truong H; Breen K; Nandakumar S; Sjoberg DD; Kemel Y; Mehta N; Lenis AT; Reisz PA; Carruthers J; Benfante N; Joseph V; Khurram A; Gopalan A; Fine SW; Reuter VE; Vickers AJ; Birsoy O; Liu Y; Walsh M; Latham A; Mandelker D; Stadler ZK; Pietzak E; Ehdaie B; Touijer KA; Laudone VP; Slovin SF; Autio KA; Danila DC; Rathkopf DE; Eastham JA; Chen Y; Morris MJ; Offit K; Solit DB; Scher HI; Abida W; Robson ME; Carlo MI
    Eur Urol; 2023 Jan; 83(1):29-38. PubMed ID: 36115772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
    Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing.
    Vogelaar IP; van der Post RS; van Krieken JHJ; Spruijt L; van Zelst-Stams WA; Kets CM; Lubinski J; Jakubowska A; Teodorczyk U; Aalfs CM; van Hest LP; Pinheiro H; Oliveira C; Jhangiani SN; Muzny DM; Gibbs RA; Lupski JR; de Ligt J; Vissers LELM; Hoischen A; Gilissen C; van de Vorst M; Goeman JJ; Schackert HK; Ranzani GN; Molinaro V; Gómez García EB; Hes FJ; Holinski-Feder E; Genuardi M; Ausems MGEM; Sijmons RH; Wagner A; van der Kolk LE; Bjørnevoll I; Høberg-Vetti H; van Kessel AG; Kuiper RP; Ligtenberg MJL; Hoogerbrugge N
    Eur J Hum Genet; 2017 Nov; 25(11):1246-1252. PubMed ID: 28875981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.